Boehringer Ingelheim is proud to provide Medical Education Grant support for specific independent educational activities for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health. An independent educational program may be at the national, regional or local level and may include but is not limited to, live and interactive didactic presentations (e.g., symposia at major educational meetings, grand rounds, regional workshops), web-based programs, print and electronic monographs and other innovative educational formats.
The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI. To contact Boehringer Ingelheim Pharmaceuticals, Inc. Medical Education Grants Department, please send an email to email@example.com. To explore an online tutorial about the Medical Education Grants application process, click here.
IMPORTANT NEW INFORMATION FOR APPLICANTS REGARDING “PHYSICIAN PAYMENTS SUNSHINE ACT”
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) has implemented new business practices to satisfy the government reporting requirements under the Physician Payments Sunshine Act, which was part of the 2010 Patient Protection and Affordable Care Act.
The Final Rule regarding transparency reporting was released by CMS on February 1, 2013 and requires applicable manufacturers (e.g., BIPI) to collect and annually report payments and other transfers of value provided to U.S.-licensed practitioners (i.e., MDs/DOs, chiropractors, dentists, podiatrists and chiropractors) and certain Teaching Hospitals (“Covered Recipients”). BIPI provides both direct and indirect transfers of value to Covered Recipients through medical education grants.
Beginning January 1, 2016 CMS has removed the CME exclusion from Open Payments reporting. The exclusion allowed applicable manufacturers (AM) to exclude reporting payments or transfers of value to faculty of accredited CME programs. The result of this change is that, starting in 2016, when an applicable manufacturer provides an indirect payment or other transfer of value to a continuing education organization for a continuing education event to physicians, and knows or finds out the identity of the physician attendees/speakers within the reporting year or by the end of the second quarter of the following reporting year, that payment must be reported to CMS within 30 days of the transfer of value.
Due to this change, Boehringer Ingelheim Pharmaceuticals, Inc. will begin to report data on transfers of value for all covered recipients regardless of program accreditation after January 1, 2016. To provide greater clarity surrounding BIPI’s reporting requirements as it pertains to the” Physician Payments Sunshine Act” under medical education grants, please refer to the document “Medical Education Grants Sunshine Reporting Requirements”.
This document will describe the grant recipient’s (educational provider’s) responsibilities to report to BIPI certain indirect payments to Covered Recipients. The document addresses those scenarios considered relevant by BIPI for reporting which are inclusive of speaker and attendee payment reporting for: (1) accredited HCP education, (2) non-accredited HCP education, and (3) non-accredited patient and community medical education.
For more information, please contact the Medical Education and Research Grants Office @ firstname.lastname@example.org.
Boehringer Ingelheim Pharmaceuticals, Inc. considers funding of activities both independently and through its alliance arrangement with Lilly USA, Inc. in a variety of areas including:
To view Therapeutic Areas of interest and begin the process of applying for a Medical Education grant within supported by the Boehringer Ingelheim Pharmaceutical Inc (BIPI) and Eli Lilly and Company (Lilly) global Alliance agreement, click here.
Funding may be limited or exhausted in some therapeutic areas. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes. To review these objectives, please click on the therapeutic area of interest above. Boehringer Ingelheim Pharmaceuticals, Inc. considers support for the following grant types: